Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness and Safety of Consolidative Brentuximab Vedotin (BV) Treatment Administered to Hodgkin's Lymphoma (HL) Patients That Had Undergone Autologous Stem Cell Transplant (ASCT). Prospective, Multicenter, Observational Study

NCT05100056 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT05100056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05100056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness and Safety of Consolidative Brentuximab Vedotin (BV) Treatment Administered to Hodgkin's Lymphoma (HL) Patients That Had Undergone Autologous Stem Cell Transplant (ASCT). Prospective, Multicenter, Observational Study
Lead sponsor
Takeda
Phase
Observational
Overall status
Recruiting
Start date
March 8, 2022
Completion date
January 13, 2027
Enrollment
70 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma